CEO David Mack was paid $1,665,191 in fiscal year 2025, ↓ down 65.0% from fiscal year 2024 (SEC filing 0001140361-26-016038 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,665,191 ↓ David Mack total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| David Mack | $628,461 | $0 | $0 | $752,320 | $284,410 | $0 | $0 | $1,665,191 |
| President, Chief Executive Officer and Director | ||||||||
| Pharm.D. Deepika Jalota | 478,429 | 0 | 0 | 282,120 | 174,638 | 0 | 0 | 935,187 |
| Chief Development Officer | ||||||||
| Robert Ticktin | 450,000 | 0 | 0 | 249,206 | 162,000 | 0 | 0 | 861,206 |
| General Counsel & Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| David Mack | $1,665,191 | $4,760,281 | — | ↓ −3,095,090 |
| Pharm.D. Deepika Jalota | 935,187 | 1,929,014 | — | ↓ −993,827 |
| Robert Ticktin | 861,206 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read PMV Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper PMVP reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name PMVP as a peer is temporarily unavailable — recheck shortly.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Mack | OPTION | 2025-03-03 | — | — | 800,000 | — | $752,320 |
| Carol Gallagher, Pharm.D | OPTION | 2025-03-03 | — | — | 300,000 | — | 282,120 |
| Robert Ticktin | OPTION | 2025-03-03 | — | — | 265,000 | — | 249,206 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Mack | $0 | $0 | $752,320 | 0.0% |
| Carol Gallagher, Pharm.D | 0 | 0 | 282,120 | 0.0% |
| Robert Ticktin | 0 | 0 | 249,206 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Mack | Option | 220,001 | 1.48 | — |
| Robert Ticktin | Option | 87,928 | 1.8 | — |
| Robert Ticktin | Option | 215,313 | 1.32 | — |
| David Mack | Option | 213,433 | 1.48 | — |
| David Mack | Option | 270,790 | 1.8 | — |
| David Mack | Option | 650,000 | 1.32 | — |
| David Mack | Option | 117,238 | 1.8 | — |
| David Mack | Option | 50,429 | 1.48 | — |
| David Mack | Option | 83,335 | 1.48 | — |
| David Mack | Option | 243,750 | 1.32 | — |
| Robert Ticktin | Option | 57,988 | 1.48 | — |
| Robert Ticktin | Option | 61,334 | 1.48 | — |
The company's compensation program is designed to attract, motivate, and retain talented executives by providing competitive base salaries and annual bonuses tied to the achievement of development, pipeline, and corporate goals, as well as long-term equity incentives to align executive interests with shareholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Charles M. Baum, M.D., Ph.DIndependent · Compensation · Nominating and Corporate Governance (Chair) | $53,000 | $0 | $21,691 | $0 | $100,000 | $174,691 |
| Arnold Levine, Ph.DIndependent | 40,000 | 0 | 21,691 | 0 | 100,000 | 161,691 |
| Richard Heyman, Ph.DIndependent · Board Chair · Audit · Compensation (Chair) · Nominating and Corporate Governance | 96,500 | 0 | 21,691 | 0 | 0 | 118,191 |
| Laurie StelzerIndependent · Audit (Chair) · Compensation | 60,000 | 0 | 21,691 | 0 | 0 | 81,691 |
| Kirsten FlowersIndependent · Audit | 47,500 | 0 | 21,691 | 0 | 0 | 69,191 |
| Carol Gallagher, Pharm.DIndependent · Nominating and Corporate Governance | 44,000 | 0 | 21,691 | 0 | 0 | 65,691 |
| David H. Mack, Ph.DEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $341,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $200,000 |
| Total cost of the board | $541,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PMV Pharmaceuticals | 2025 | David Mack | $628,461 | $0 | $752,320 | $284,410 | $1,665,191 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, David Mack | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Summary Compensation Table” · page 20. As printed: 1,665,191. Filing ↗machine: r2 · c27 · span 469868–469877 |
| 2 | Section 01, Pharm.D. Deepika Jalota | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Summary Compensation Table” · page 20. As printed: 935,187. Filing ↗machine: r5 · c27 · span 484258–484265 |
| 3 | Section 01, Robert Ticktin | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Summary Compensation Table” · page 20. As printed: 861,206. Filing ↗machine: r8 · c27 · span 497937–497944 |
| 4 | Section 03, David Mack OPTION | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. Filing ↗machine: span 519433–519440 |
| 5 | Section 03, Carol Gallagher, Pharm.D OPTION | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. Filing ↗machine: span 522125–522132 |
| 6 | Section 03, Robert Ticktin OPTION | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. Filing ↗machine: span 525037–525044 |
| 7 | Section 08, Charles M. Baum, M.D., Ph.D | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Director Compensation”. As printed: 174,691. Filing ↗machine: span 381095–381276 |
| 8 | Section 08, Arnold Levine, Ph.D | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Director Compensation”. As printed: 161,691. Filing ↗machine: span 404665–404849 |
| 9 | Section 08, Richard Heyman, Ph.D | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Director Compensation”. As printed: 118,191. Filing ↗machine: span 377421–377645 |
| 10 | Section 08, Laurie Stelzer | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Director Compensation”. As printed: 81,691. Filing ↗machine: span 408131–408352 |
| 11 | Section 08, Kirsten Flowers | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Director Compensation”. As printed: 69,191. Filing ↗machine: span 385337–385559 |
| 12 | Section 08, Carol Gallagher, Pharm.D | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Director Compensation”. As printed: 65,691. Filing ↗machine: span 388852–389074 |
| 13 | Section 08, David H. Mack, Ph.D | DEF 14A | 2026-04-22 | 0001140361-26-016038 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 16 | Section 09b board cost (computed) | Computed | — | — | Cash 341,000 + equity 0 + all other 200,000 = 541,000, summed across the director compensation table rows.machine: formula: Σ = 541,000 |
| 17 | PMV Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016038 | CEO total compensation as printed in PMV Pharmaceuticals's own proxy. As printed: 1,665,191. Filing ↗machine: r2 · c27 · span 469868–469877 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.